French firms call for action to boost industry in "crucial" presidential election year
This article was originally published in Scrip
In the run-up to the French presidential elections next month, a group of domestic pharmaceutical companies has issued a "white paper" drawing the candidates' attention to the needs of an industry facing a severe public image problem, higher taxes and a complex set of procedures that it says are hindering new drugs' access to the market.
You may also be interested in...
Roche plans to appeal against a penalty imposed by the Romanian competition authorities for implementing strategies that were said to delay the entry of competing biosimilar and generic products.
The EU association representing parallel traders says cheaper parallel imports are vital in keeping medicines affordable for member states.
The latest drug safety actions by the European Medicines Agency affect products for dermatological use and vaginal atrophy.